Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 91 (3), 539-551

Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy: Conclusions From a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Collaborators, Affiliations

Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy: Conclusions From a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Timothy H J Goodship et al. Kidney Int.

Abstract

In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement plays a primary role in disease pathogenesis. Herein we report the outcome of a 2015 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference where key issues in the management of these 2 diseases were considered by a global panel of experts. Areas addressed included renal pathology, clinical phenotype and assessment, genetic drivers of disease, acquired drivers of disease, and treatment strategies. In order to help guide clinicians who are caring for such patients, recommendations for best treatment strategies were discussed at length, providing the evidence base underpinning current treatment options. Knowledge gaps were identified and a prioritized research agenda was proposed to resolve outstanding controversial issues.

Keywords: C3 glomerulopathy; anti-complement therapies; atypical hemolytic uremic syndrome; complement; glomerulonephritis; kidney disease.

Similar articles

See all similar articles

Cited by 81 articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback